Nanopath Raises $25M in Series B Funding to Advance Diagnostics

Nanopath, a Cambridge, MA-based point of care diagnostics company enabling rapid molecular testing, has raised $25 million in a Series B funding round including $2M in non-dilutive grant funding.

The round was co-led by Norwest and SV Health Investors’ MedTech Convergence Fund, with participation from the Labcorp Venture Fund, alongside returning and new investors Elderberry Ventures, GingerBread Capital, and Alumni Ventures.

The company will use the funding to prepare for the commercial launch of its 15-minute vaginitis test. Planned activities include scaling manufacturing, starting an FDA 510(k) clinical study and expanding its clinical and commercial teams.

What is Nanopath?

Nanopath develop's molecular diagnostic technology designed to help clinicians conduct complex tests directly at the point of care rather than sending samples to central laboratories.

Read More:Synctera Raises $24.5M to Support Banking Platform Growth

Its platform uses proprietary biosensing technology to analyse clinical samples and deliver diagnostic results more quickly. The company's first planned product is a 15-minute test for vaginitis, a women's health condition.

The test is designed to provide results during a single healthcare visit, helping clinicians make timely decisions and reducing the need for patients to wait for laboratory results.

Nanopath aims to make advanced diagnostic testing more accessible, beginning with women's health and potentially expanding its platform to other clinical conditions.

How Much Funding Has Nanopath Raised?

Nanopath has secured $25 million in its Series B round. This includes $2 million in non-dilutive grant funding.

The announcement did not disclose the company's total funding raised or details of previous funding rounds.

Who Invested in Nanopath’s Series B?

The Series B round was co-led by Norwest and SV Health Investors’ MedTech Convergence Fund.

Other participating investors include:

• Labcorp Venture Fund
• Elderberry Ventures
• GingerBread Capital
• Alumni Ventures

The round included both returning and new investors.

Why the Funding Matters

Nanopath will use the investment to advance its 15-minute vaginitis assay towards commercial launch.

Key priorities include expanding manufacturing capacity, beginning the FDA 510(k) clinical study and hiring across clinical and commercial operations.

These steps are intended to help the company complete the development and regulatory work needed before bringing the test to market.

Who founded Nanopath?

Nanopath was founded in 2020 by Alison Burklund and Amogha Tadimety. The company is headquartered in Cambridge, Massachusetts, at The Engine, a facility built by MIT.

The company describes itself as women-led and focuses on improving access to diagnostic testing, starting with women's health.

Nanopath has developed the first clinical diagnostics platform built on plasmonic biosensing. The company's proprietary optical biosensing technology is designed to enable molecular detection without nucleic acid amplification, a step required by PCR-based tests. "We've spent years developing and pressure-testing a fundamentally new approach to molecular diagnostics for patients who have been overlooked for far too long," said Alison Burklund, Ph.D., Co-Founder & Co-CEO of Nanopath.

Market and Business Growth

Nanopath is developing its first diagnostic product for vaginitis, with a focus on delivering results during a single patient visit.

Its broader molecular testing platform is designed to support high-complexity diagnostics outside traditional laboratory settings. The company expects the technology could eventually be applied to other clinical indications.

The latest funding will support the manufacturing, clinical and commercial work required to move its first test towards market. The company has not disclosed revenue, customer or deployment figures.

What Happens Next?

Nanopath will focus on scaling manufacturing, initiating its FDA 510(k) clinical study and expanding its team.

Its immediate priority is to complete the development and regulatory milestones for the 15-minute vaginitis test. Over time, the company plans to explore additional clinical applications for its point-of-care diagnostic platform.

Read More:Nyquis Raises $6.3M Seed Funding for Grid Monitoring